SPAC Translational Development closes $172.5M IPO with full over-allotment

Translational Development Acquisition Corp.

IPO of 17.25M units at $10/unit raised $172.5M gross; units list on Nasdaq under TDACU.
Simultaneous private placement of 7.075M warrants at $1.00/warrant raised $7.075M from sponsor and underwriter.
Net proceeds of $174.225M placed in trust account; company has 18 months to complete a business combination.
Michael B. Hoffman named CEO/Chairman; Avanindra C. Das CFO; Board includes Reddy, Keith, Kestenbaum, Jarratt.
Directors appointed to audit, compensation, and nominating committees; indemnity agreements executed.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Translational Development Acquisition Corp.: Amended and restated memorandum and articles of association filed and effective (effective 2024-12-20).

Change: charter amendment
Effective: 2024-12-20

Exact text from the filing

On December 20, 2024, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended and Restated Memorandum and Articles of Association ”) with the Cayman Islands Registrar of Companies, which was effective on December 20, 2024.

View on SEC.gov

Browse all governance changes →

Translational Development Acquisition Corp. filing history →

Source: SEC EDGAR

accession 0001104659-24-132134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.